Ghost Tree Capital LLC Invests $5.17 Million in Galapagos NV (NASDAQ:GLPG)

Ghost Tree Capital LLC bought a new position in Galapagos NV (NASDAQ:GLPG) during the second quarter, Holdings Channel.com reports. The firm bought 75,000 shares of the biotechnology company’s stock, valued at approximately $5,167,000. Galapagos makes up about 1.4% of Ghost Tree Capital LLC’s portfolio, making the stock its 27th biggest holding.

A number of other institutional investors have also recently bought and sold shares of GLPG. The PNC Financial Services Group Inc. lifted its stake in Galapagos by 936.4% in the first quarter. The PNC Financial Services Group Inc. now owns 342 shares of the biotechnology company’s stock valued at $28,000 after purchasing an additional 309 shares during the last quarter. Standard Family Office LLC purchased a new position in Galapagos in the first quarter valued at approximately $33,000. Quadrant Capital Group LLC lifted its stake in Galapagos by 476.0% in the second quarter. Quadrant Capital Group LLC now owns 576 shares of the biotechnology company’s stock valued at $40,000 after purchasing an additional 476 shares during the last quarter. Atlas Capital Advisors LLC lifted its stake in Galapagos by 201.1% in the second quarter. Atlas Capital Advisors LLC now owns 1,048 shares of the biotechnology company’s stock valued at $72,000 after purchasing an additional 700 shares during the last quarter. Finally, Knott David M purchased a new position in Galapagos in the first quarter valued at approximately $77,000. Institutional investors and hedge funds own 11.27% of the company’s stock.

Several research firms recently commented on GLPG. Raymond James set a $65.80 price objective on Galapagos and gave the company a “buy” rating in a research note on Thursday, July 15th. Deutsche Bank Aktiengesellschaft cut shares of Galapagos from a “buy” rating to a “hold” rating and set a $50.00 target price on the stock. in a report on Friday, August 6th. UBS Group reissued a “neutral” rating on shares of Galapagos in a report on Friday, August 27th. Zacks Investment Research cut shares of Galapagos from a “hold” rating to a “sell” rating in a report on Tuesday, August 10th. Finally, Barclays cut shares of Galapagos from an “overweight” rating to an “equal weight” rating in a report on Thursday, August 19th. Three investment analysts have rated the stock with a sell rating, nine have issued a hold rating and three have assigned a buy rating to the company’s stock. Based on data from MarketBeat, Galapagos presently has a consensus rating of “Hold” and a consensus price target of $103.60.

Shares of Galapagos stock traded up $0.65 during trading on Friday, hitting $55.94. The stock had a trading volume of 9,261 shares, compared to its average volume of 297,209. The firm has a market cap of $3.67 billion, a price-to-earnings ratio of -10.36 and a beta of 0.54. Galapagos NV has a 12 month low of $54.55 and a 12 month high of $148.68. The business’s 50-day moving average is $59.62 and its 200 day moving average is $70.94.

Galapagos Profile

Galapagos NV is a biotechnology company, which engages in the identification and development of small molecule and antibody therapies. It operates through the Research & Development and Fee-for-Services segment. The company was founded by Onno van de Stolpe, Rudi Pauwels, and Helmuth van Es on June 30, 1999 and is headquartered in Mechelen, Belgium.

Featured Story: How to Use the MarketBeat Retirement Calculator

Want to see what other hedge funds are holding GLPG? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Galapagos NV (NASDAQ:GLPG).

Institutional Ownership by Quarter for Galapagos (NASDAQ:GLPG)

Receive News & Ratings for Galapagos Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Galapagos and related companies with MarketBeat.com's FREE daily email newsletter.